Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have to get rid of the nerveous nellies
who have no idea of how Valuable DECN is
and will become;O)
Gio
Anoter day ,Another week with no sales!
What are the sales teams doing?
They are ineffective.
Fire the high priced lot of them.
and make sales dependent on commision
T-R1 Thank you
Gio
I think he meant the airline industry.
What is your postion if I may ask.
It would help us all out if you see the security from the inside of the airport and could report.
Thank you
Gio
On Topic: Runaway, Everybody Up & Dancing
Where will DECN close today?
My wag up$.27
WoW
No Sellers Today!!!!
Gio
Thank you to the two Mr.S!!!
It`s gonna be a great day.
Gio
Does anyone have the link to the J&J lawyer admitting
They do not have a patent on their Life-Scan strip?
TIA
Gio
J&J Faces Contempt For Contacting Glucose-Strip Sellers
ByJonathan Randles0 Comments
Law360, New York (August 30, 2013, 4:44 PM ET) -- The Johnson & Johnson subsidiary that makes OneTouch Ultra glucose monitors could be held in contempt for using privileged information to contact distributors of allegedly patent-infringing glucose test strips after obtaining a preliminary injunction, a California federal judge said Wednesday.
J&J's LifeScan Inc. unit violated a protective order when it used confidential information to contact distributors for defendants Shasta Technologies LLC, Decision Diagnostics Corp., Pharma Tech Solutions Inc. and Conductive Technologies Inc., U.S. District Judge William H. Orrick ruled.
The court ordered LifeScan to explain why...
To view the full article, take a free trial now.
Already a subscriber? Click here to login
A Great Name Change would Give IMSC Instant Recognition
in the Bomb and Explosive World.
A name change is essential.
Implant Science? Old biz old name
Gio
This % gain will wake people up.
You guys worry too much
This is going to be the
biggest winner of your
life scan err LIFE TIME
Gio
Dancing
Making Money Is The Best Revenge;0)
A little Celebration for DECN LONGS
Everybody up and dancing;0)
Thank you
A buddy bought high and he is very negative.
I cannot wake him up to the New DECN;0)
GLTA
Gio
Sales please.
Last weeks news was out last spring
Does anyone know the historical high and low stock price of DECN?
Thanks all
Here is to a great week!
Gio
Another week with no news?
This is terrible.
Coghlin Companies, representing more than 126 years of manufacturing experience and leadership. Subsidiaries include: Columbia Tech, which provides turnkey manufacturing services to a diverse customer base, including OEMs in the bio-science, semiconductor, LED, medical device, green energy technology, data storage, and automation systems and controls industries; DCI Engineering, an engineering design and pre-production support services company; and Cogmedix, an FDA compliant and ISO 13485 certified medical subassembly and finished medical device contract manufacturer. Sign up for the Coghlin Companies e-Newsletter at http://coghlincompanies.com/newsletter-signup.php.
Yes IMSC will train the workers.
Yes IMSC certainly HOPES they can keep these guys going 24/7 as we all do. However if this is not the case.. kay cera cera
July 18 was a long time ago
2 months without a sale.
Another day with No News!
What is the sales team doing?
Even a caveman can understand;o)
One sells
News from IMSC been a long time coming
I see you did not have a chance to read that article.
IMSC was wise not to pursue drugs.
They have the best ETD solution.
Until I read that article I had hope
IMSC had a chance in that market also.
Gio
A very bad thing:O)
Gio
DECN $20 @ share is a realistic Expectation.
Walmart contract What is that worth?
Walmart will have Genstrip in 5000 physical
locations and on the web.
Forget the debt
New innovative technology is going to blow the doors off.
That debt is nothing now.
Does IMSC have competition in Drug Trace detection?
There is a much cheaper drug detection unit that is being used today by police nationwide.
Google it.
Gio
that is not DECN making dough that is the drug store that is over charging for genstrips
gensstrip will make no money at $28 dollars
people would stick with J&J for a $2 difference
Gio
Handheld drug analyzer eyed as ‘game-changer’ for cops
Tuesday, September 10, 2013 ..
- See more at: http://bostonherald.com/business/business_markets/2013/09/handheld_drug_analyzer_eyed_as_game_changer_for_cops#sthash.baEIwDFY.dpuf
Handheld drug analyzer eyed as ‘game-changer’ for cops - See more at: http://bostonherald.com/business/business_markets/2013/09/handheld_drug_analyzer_eyed_as_game_changer_for_cops#sthash.t7VcJi3I.dpuf
DECN Buzz will be Fantastic.
Every diabetic will be praising the savings they will
achive. A major medical expense cut in half or more.
This will save people billions. Huge news.
Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
Yeaw J, Lee WC, Aagren M, Christensen T.
Source
Economics and Outcomes Research, IMS Consulting Group, 3 Lagoon Dr., Ste. 230, Redwood City, CA 94065, USA. jyeaw@imscg.com
Abstract
BACKGROUND:
People with diabetes are at an increased risk of developing numerous complications, resulting in increased health care expenditures, economic burden, and higher mortality. For patients using an insulin pump or multiple insulin injections, self-monitoring of blood glucose (SMBG) is recognized as a core component of effective diabetes self-management. However, little is known about the real-world frequency and true costs associated with SMBG as a percentage of an insulin regimen in the United States.
OBJECTIVE:
To evaluate SMBG frequency, SMBG-related costs (including blood glucose test strips and testing supplies), and insulin therapy costs among insulin-dependent patients with diabetes and at least 1 pharmacy claim for blood glucose testing strips during a 12-month follow-up period.
METHODS:
A retrospective database analysis was conducted using the IMS LifeLink Health Plan Claims database to capture the frequency and costs associated with SMBG in relation to a specific insulin regimen, and SMBG expenditure compared with other treatment costs. The study employed a retrospective cohort analysis of patients with 2 or more claims for insulin between January 1, 2007, and June 30, 2009, with the first such claim representing the index date. All patients were required to have 6 months of pre-index continuous enrollment (pre-index period) and 12 months of post-index continuous enrollment (follow-up period). Patients were also required to have a diagnosis of diabetes in the pre-index period and to have no gaps of more than 90 days between consecutive insulin claims during the 360-day follow-up period. Patients without at least 1 pharmacy claim for blood glucose testing strips during the 12-month follow-up period and patients with pharmacy claims with extreme values (greater than 1,500 strips) were excluded. Depending on the insulin types used within the 30 days immediately following their index date, patients were subcategorized into 1 of 4 insulin regimen groups (basal, bolus, premixed, or basal-bolus). Patients' frequency of blood glucose testing was measured throughout their 12-month post-index follow-up period through analysis of clinical codes found on pharmacy claims. Quantity supplied fields on pharmacy claims were used to calculate total tests utilized over the follow-up period (e.g., 50 test strips dispensed=50 tests assumed). Insulin-related costs were also evaluated for the 12-month follow-up period.
RESULTS:
Among an initial sample of 373,946 patients with at least 2 claims for insulin between January 1, 2007, and June 30, 2009, 45,555 patients (12.2%) formed the final overall cohort who met the inclusion and exclusion criteria. SMBG-related pharmacy costs accounted for 27% of the insulin-and SMBG-related treatment costs for insulin users with an average $772 per patient in prescription testing strips and supplies versus $2,078 for insulin prescriptions and supplies. With an overall mean utilization for pharmacy-based SMBG testing of 764.3 strips per year, the average cost per testing strip was $0.98. Annual SMBG costs were 24.5% of total insulin and SMBG-related pharmacy costs for the basal insulin group compared with 35.8% for bolus, 21.0% for premixed, and 26.4% for basal-bolus.
CONCLUSION:
For insulin users with at least 1 pharmacy claim for glucose test strips, SMBG-related costs accounted for about one-fourth of total insulin and SMBG-related pharmacy costs.
PMID: 22235952 [PubMed - indexed for MEDLINE] Free full text
http://www.ncbi.nlm.nih.gov/pubmed/22235952
Wow that add says"$9.95 or less for a box of 50!
Go DECN;0)
http://www.shastagenstrip.com/
IMSC should be bought out
if they cannot sell their ETD units
Bolduc is making over half a million a year now
How about pay for performance?
Magic Eight Ball when will IMSC have another
significant sale?
Just asking
Gio
J&J 100% Over Priced $32.99 Compared to Genstrip $17.49
for 50 strips;O)
ONE TOUCH Ultra Test Strips - Blue - 50 CT
The OneTouch® Ultra Test Strips with FastDraw Design make blood glucose testing fast, easy, and less painful. The OneTouch® Ultra Meter gives results in just 5 seconds and requires just a speck of blood, making the test an easier process for anyone with Diabetes.
In Stock
$32.99
Here we go it has been 4 months
since Mcgann(sp?) said this was a layup.
Nobody Knows About DECN;0) Lucky Us!
Time to load up.
Gio